{"url_path":"/sec/sxtp/8-k/2026-07-20/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-20","source_url":"https://www.sec.gov/Archives/edgar/data/1946563/0001213900-26-079612-index.html","accession_number":"0001213900-26-079612","cik":"0001946563","ticker":"SXTP","issuer_name":"60 DEGREES PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1946563/0001213900-26-079612-index.html","primary_entity_key":"0001946563","primary_entity_name":"60 DEGREES PHARMACEUTICALS, INC."},"word_count":346,"has_tables":true,"body_markdown":"false\n0001946563\nDC\n\n0001946563\n\n2026-07-20\n2026-07-20\n\n0001946563\n\nSXTP:CommonStockParValue0.0001PerShareMember\n\n2026-07-20\n2026-07-20\n\n0001946563\n\nSXTP:WarrantsEachWarrantToPurchaseOneShareOfCommonStockMember\n\n2026-07-20\n2026-07-20\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE\nCOMMISSION**\n\n**WASHINGTON, D.C. 20549**\n\n \n\n**FORM 8-K**\n\n \n\n**CURRENT REPORT**\n\n**PURSUANT TO SECTION\n13 OR 15(d)**\n\n**OF THE SECURITIES EXCHANGE\nACT OF 1934**\n\n \n\nDate of Report (Date of\nearliest event reported): July 20, 2026\n\n \n\n**60 DEGREES PHARMACEUTICALS, INC.**\n\n(Exact name of registrant\nas specified in its charter)\n\n \n\n**Delaware**\n \n**001-41719**\n \n**45-2406880**\n\n(State or other jurisdiction\n\nof Incorporation)\n \n(Commission File Number)\n \n(IRS Employer\n\nIdentification Number)\n\n \n\n**1025 Connecticut Avenue NW Suite 1000,**\n\n**Washington, D.C.**\n\n \n**20036**\n\n(Address of registrant’s principal executive office)\n \n(Zip code)\n\n** **\n\n**(202) 327-5422**\n\n(Registrant’s telephone\nnumber, including area code)\n\n \n\n**Not Applicable**\n\n(Former name or former\naddress, if changed since last report)\n\n \n\nCheck the appropriate box below if the Form\n8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General\nInstruction A.2. below):\n\n \n\n☐\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n☐\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n☐\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n**☐**\n**Pre-commencement\ncommunications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))**\n\n \n\nSecurities registered\npursuant to Section 12(b) of the Act:\n\n \n\n**Title of each class**\n \n**Trading symbol(s)**\n \n**Name of each exchange on which registered**\n\nCommon Stock, par value $0.0001 per share\n \nSXTP\n \nThe Nasdaq Stock Market LLC\n\nWarrants, each warrant to purchase one share of Common Stock\n \nSXTPW\n \nThe Nasdaq Stock Market LLC\n\n \n\nIndicate by check mark whether the registrant\nis an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the\nSecurities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging\ngrowth company ☒\n\n \n\nIf an emerging growth company, indicate by\ncheck mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting\nstandards provided pursuant to Section 13(a) of the Exchange Act. ☐"}